Clene to Attend the 14th Annual Benchmark Discovery One-on-One Investor Conference

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 20 2025

0mins

Source: Globenewswire

Company Overview: Clene Inc. is a clinical-stage biopharmaceutical company focused on enhancing mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and MS.
Investor Conference Participation: Clene will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York, hosting individual investor meetings.
Therapeutic Focus: The company's investigational therapy, CNM-Au8®, aims to improve the survival and function of central nervous system cells by targeting mitochondrial function and reducing oxidative stress.
Contact Information: For investor inquiries, Kevin Gardner from LifeSci Advisors can be contacted via email or phone for further information.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free